Refractory Natural Killer/T-cell Lymphoma
1 clinical trials · Condition
◉ Watch Refractory Natural Killer/T-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy (NCT04763616) | Won Seog Kim | 2021-06-25 |
Track Refractory Natural Killer/T-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.